Cost-effectiveness analysis of n-3 polyunsaturated fatty acids (PUFA) after myocardial infarction: results from Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)-Prevenzione Trial.

摘要: Objective: To estimate the cost effectiveness of treatment with n-3 polyunsaturated fatty acids (PUFA) for secondary prevention after myocardial infarction (MI). Design and setting: The cost-effectiveness analysis PUFA MI was based on morbidity mortality data use resources obtained prospectively during 3.5 year follow-up period Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto (GISSI)-Prevenzione study. took into account incremental number life-years gained costs hospital admissions, diagnostic tests drugs, applying a 5% discount rate. value money assessed using ratio needed to treat (NNT) approach. Perspective: Third-party payer. Main outcome measures results: in base case scenario 24 603 euro (EUR, 1999 values) life-year (95% confidence interval: 22 646 26 930). Sensitivity included extremes, producing estimates varying from EUR15 721 EUR52 524 gained. 172 patients would need be treated PUFA, at an annual EUR68 000, order save 1 patient. This is comparable NNT value, associated simvastatin, but less costly than that pravastatin. Conclusions: long term other drugs recently introduced routine care MI. Since clinical benefit provided by additive, this therapy should added established practice, additive costs.